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Abstract
Summary A Swiss-specific FRAX® model was developed.
Patient profiles at increased probability of fracture beyond
currently accepted reimbursement thresholds for bone mineral
density (BMD) measurement by dual X-ray absorptiometry
(DXA), and osteoporosis treatment were identified.
Introduction This study aimed to determine which constella-
tions of clinical risk factors, alone, or combined with BMD
measurement by DXA, contribute to improved identification
of Swiss patients with increased probability of fracture.
Methods The 10-year probability of hip and any major
osteoporotic fracture was computed for both sexes, based on
Swiss epidemiological data, integrating fracture risk and death
hazard, in relation to validated clinical risk factors, with and
without BMD values.
Results Fracture probability increased with age, lower body
mass index (BMI), decreasing BMD T-score, and all clinical
risk factors used alone or combined. Several constellations of
risk factor profiles were identified, indicating identical or
higher absolute fracture probability than risk factors currently
accepted for DXA reimbursement in Switzerland.With identi-
cal sex, age and BMI, subjects with parental history of hip
fracture had as high a probability of any major osteoporotic
fracture as patients on oral glucocorticoids or with a prevalent
fragility fracture. The presence of additional risk factors
further increased fracture probability.
Conclusions The customised FRAX® model indicates that
a shift from the current DXA-based intervention paradigm,
toward a fracture risk continuum based on the 10-year
probability of any major osteoporotic fracture may improve
identification of patients at increased fracture risk.
Keywords Clinical risk factors . FRAX® . Hip fracture .
Osteoporotic fracture . 10-year fracture probability
Introduction
Osteoporotic fractures are one of the leading causes of
morbidity in men and women living in industrialised
countries. Switzerland belongs to the countries at highest risk
for osteoporotic fractures [1, 2]. Life expectancy at birth is
amongst the highest worldwide [3], and Switzerland ranks
second worldwide with regard to the proportion of elderly in
its population [4]. Furthermore, the number of persons older
than 65 years is expected to double between the years 2005
and 2050 [5]. Based on health economic modelling, ageing
of the population is expected to lead to a massive increase in
health expenditure due to osteoporotic fractures in coming
decades if current diagnostic and treatment behaviour
remains unchanged [6]. Thus, the reality of osteoporosis in
Switzerland today may be considered as a paradigm for the
future of other industrialised countries.
The current gold standard for the diagnosis of osteopo-
rosis is the measurement of bone mineral density (BMD) by
dual X-ray absorptiometry (DXA). The WHO proposed an
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operational definition of osteoporosis as a BMD that lies
2.5 SD or more below the average mean value of young
healthy women (T-score≤−2.5 SD), accepting by inference
the same definition for men [7, 8], more recently made
explicit [9]. This definition has been readily accepted by
most regulatory agencies and used as a cut-off for limiting
treatment access. In Switzerland, bisphosphonates are the
mainstay of drug therapy for osteoporosis and are generally
reimbursed if the patient has documented osteoporosis
defined as a BMD T-score ≤−2.5 SD measured by DXA
and/or a fracture. Reimbursement of DXA examination is
mainly restricted to patients with clinically overt osteopo-
rosis or a fracture caused by a low-energy trauma. It is also
possible for those with hypogonadism, gastrointestinal dis-
eases leading to malabsorption, primary hyperparathyroidism
and chronic users of glucocorticoids. Therefore, currently
reimbursed DXA indications exclude patients presenting with
other well-known major risk factors for osteoporosis, such
as a parental history of hip fracture, tobacco and/or alcohol
abuse and rheumatoid arthritis.
Prospective epidemiological studies have shown that,
although fracture risk increases with decreasing BMD, many
fractures occur in subjects with a BMD T-score value above
the operational threshold [10–12]. The recent Swiss Osteo-
Care survey measured BMD by DXA at the lumbar spine,
the total hip and/or the femoral neck in 1,152 patients
presenting with a fragility fracture at an emergency ward.
This study found that 46% of patients had osteoporosis, 35%
had osteopenia (−2.5<T-score≤−1 SD) and 19% had normal
BMD (T-score>−1.0 SD) [12]. Thus, 54% of all patients
with a fragility fracture have bone mass above the diagnostic
threshold for osteoporosis.
Recently, the use of clinical risk factors has been shown
to enhance the performance of BMD in the prediction of
hip and osteoporotic fractures in men and women [13]. In
order to identify the major clinical risk factors for osteopo-
rotic fracture, the data from nine prospective primary cohorts
and 11 prospective validation cohorts, including more than
275,000 persons corresponding to 1.4 million person-years
with more than 22,711 reported fractures, were analysed
[13]. The validation analysis included the results from the
Swiss SEMOF-cohort [14]. In addition to any prior fragility
fracture that occurred after age 50, age, sex, body mass
index and additional risk factors were considered. These
included prior use of glucocorticoids, secondary osteopo-
rosis, rheumatoid arthritis, a parental history of hip fracture,
current cigarette smoking, and alcohol intake of three or
more units/day. These factors were identified as clinical
predictors of osteoporotic fracture probability, independent-
ly of BMD [13]. Taking into account local epidemiological
data, the impact of these risk factors on the 10-year absolute
probability of fracture can allow for country-specific
prediction of individual fracture probability, based on the
individual risk factor profile. This case-finding algorithm,
known as FRAX®, has been developed in collaboration with
the WHO and has been customised to the epidemiology of
several countries including the UK [1], the USA [15] and
Japan [16].
In an earlier publication, all of the elements required to
populate a Swiss-specific FRAX® model were validated
[17]. The aim of the present study was to determine which
constellations of clinical risk factors, alone or in combina-
tion, and with or without a BMD measurement by DXA,
would contribute to improved identification of patients with
increased probability of fracture in the Swiss environment.
Methods
The effect of BMD, gender and age on the 10-year absolute
probability of hip and any major osteoporotic fracture (hip,
vertebral, distal radius and proximal humerus) by 5-year
age groups has been previously reported [17]. Baseline data
included the incidence of hospitalisation for fractures and
osteoporotic fractures in the year 2000 as published by the
Swiss Federal Office of Statistics [2] and results from the
prospective Swiss OsteoCare survey [12] standardised for
hip fractures. These values were extrapolated for the determi-
nation of the total number of major clinical osteoporotic
fractures (hospitalised and non-hospitalised). Additional
baseline data included death risk and incidence tables for
Switzerland in 1999 published by the WHO [18] and femoral
neck BMD T-scores derived from the National Health and
Nutrition Examination Survey (NHANES) III data for
Caucasian women aged 20–29 years [19].
The clinical risk factors identified in the nine prospective
validated cohorts [13] were applied to the Swiss epidemio-
logical data using the methodology previously described for
the development of the FRAX® fracture probability assess-
ment model in the UK [20]. Briefly, BMI, as mathematically
derived from height and weight, BMD T-scores at the
femoral neck, and age between 50 and 90 years were used as
continuous variables. The following clinical risk factors,
consistently reported in all primary cohorts, were used as
dichotomous variables: current cigarette smoking, alcohol
intake of three or more units daily, rheumatoid arthritis, other
causes of secondary osteoporosis, current and prior use of
glucocorticoids, previous fragility fracture, including mor-
phometric vertebral fractures discovered by chance on an
X-Ray, and parental history of hip fracture. ‘Use of gluco-
corticoids’ depicts either current or previous treatment with
oral glucocorticoids with an exposure period of ≥3 months at
a dose of ≥5 mg daily of prednisolone or equivalent doses of
other glucocorticoids. The effects of all these factors on the
10-year probability of fracture were modelled for hip and
major clinical osteoporotic fractures, with and without BMD
382 Osteoporos Int (2010) 21:381–389
for both sexes. For each model, fracture and death were
computed as continuous hazard functions using a Poisson
regression as previously reported [20].
Importantly, rheumatoid arthritis was considered sepa-
rately from other causes of secondary osteoporosis. The
presence of rheumatoid arthritis was shown to increase
fracture probability independently of BMD and glucocorti-
coid intake [21]. Other forms of secondary osteoporosis,
such as hypogonadism or premature menopause (<45 years)
[22–24], inflammatory bowel diseases [25–28], immobili-
sation due to spinal cord injury [29] and thyroid disorders
[30], are generally associated with increased fracture
probability; however, whether these are independent of
BMD remains controversial. Therefore, for FRAX® mod-
elling purposes, other causes of secondary osteoporosis
were attributed the same level of risk as rheumatoid arthritis
in the absence of a BMD value and no additional risk if a
BMD value was available. In the presence of rheumatoid
arthritis and another cause of secondary osteoporosis, the
risks allocated are those for rheumatoid arthritis only. BMD
refers to the femoral neck BMD as measured by DXA in
men or women. For the purpose of this manuscript, BMI
was set at 25 kg/m2 and age at 65 years unless otherwise
indicated.
Results
Effect of BMI and BMD on fracture probability
At any age, the absolute 10-year fracture probability was
higher in men and women with lower BMI values (Fig. 1).
In addition, the contribution of a low BMI on fracture pro-
bability was higher in elderly compared to younger patients.
At any BMI value, 90-year old patients had a lower absolute
10-year fracture probability than 80-year old patients, the
effect being more pronounced in men than in women. This
reflects the fact that in the FRAX® model, death hazard from
all causes and fracture probability are competing events. As
shown in Fig. 2, absolute 10-year fracture probabilities
increased exponentially with decreasing T-score values. The
effect of BMD on fracture probability again decreased in very
old men and women, indicating that, with advanced age, there
is a higher probability of dying from any other competing
cause rather than sustaining an osteoporotic fracture.
Fracture probability in the presence of single risk factors
Fracture probability was always found to be higher in
women than in men. This was consistent across any given
age, BMI value, T-score value, and for any single risk
factor. In the absence of any validated risk factor selected
for FRAX® modelling, the 10-year probability of a major
osteoporotic fracture at age 65 years and at a BMI of 25 kg/m2
(base case) was 5.6% in men and 9.5% in women. The data
presented in Table 1 indicate that the presence of risk
factors increased this base case probability. Large increases
in fracture probability were observed in the case of a
previous fragility fracture or of parental history of hip
fracture. Both of these factors doubled the probability,
reaching 11.0% and 18.0% in men and women, respec-
tively. At age 65, a BMD T-score of −2.5 SD measured at
the femoral neck increased 10-year fracture probability to
11.0% and 14.0% in men and women, respectively. This
fracture probability further increased up to 18.0% in men
Fig. 1 Absolute 10-year major fracture probability at various levels of
BMI (kg/m2) and at different ages for Swiss men and women, without
clinical risk factors
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and 24.0% in women, depending on which associated single
clinical risk factor was present.
As shown in Table 2, the 10-year absolute probability of
any major osteoporotic and hip fracture in the presence of a
single risk factor increased with advancing age in both
sexes. Between a 50-year-old man without risk factors and
an 80-year-old man with a parental history of hip fracture,
the individual probability of any major osteoporotic fracture
increased 6.5-fold (from 3.4% to 22.0%). In women, this
probability increased 10.2-fold. For equivalent scenarios, the
probability of suffering a hip fracture increased 75-fold in
men and 100-fold in women from base line levels.
Fracture probability was found to increase with decreas-
ing BMD T-score values in both sexes, as shown in Table 3
and Fig. 2. In the absence of any risk factor, the 10-year
probability of a major osteoporotic fracture for a 65-year-old
woman presenting with the commonly accepted treatment
threshold T-score of −2.5 SD was 14.0%. This fracture
probability was equal to or lower than that of a woman with
a T-score of −2.0 SD and either rheumatoid arthritis, present or
past glucocorticoid treatment, previous fragility fracture
during adulthood or parental history of hip fracture. The
fracture probability was also lower than that of a woman with
a T-score of −1.0 SD and a parental history of hip fracture. In
addition, in men without clinical risk factors and a T-score of
−2.5 SD, the absolute 10-year fracture probability for any
major osteoporotic fracture was 11.0%. With a parental
history of hip fracture, the same level of absolute fracture
probability was achieved at a T-score of −1.0 SD. However,
based on the current thresholds for reimbursement, treatment
with a bisphosphonate would be reimbursed in the former
case, but not in the latter, despite the probability of a fracture
being equal in both cases.
Fracture probability with multiple risk factors
The absolute 10-year major osteoporotic or hip fracture
probability was found to increase exponentially with the
number of associated risk factors. In the absence of an
available BMD T-score value and in the base case (BMI of
25 kg/m2 and age of 65 years), the probability of any major
osteoporotic fracture was increased 8.2-fold in men presenting
with all risk factors (46.0%) compared to men with no risk
factors (5.6%) and 7.5-fold (71.0% and 9.5%, respectively) in
women as shown in Table 4. In the case of patients having
all risk factors, a BMD T-score of −2.5 SD compared to no
BMD value available contributed only modestly to fracture
probability in women (72.0% vs. 71.0%) but considerably
more in men (58.0% vs. 46.0%). These results indicate that,
depending on sex and age, the relevance of a T-score value
with regard to fracture probability varied.
At the age of 65 and for any major osteoporotic
fracture resulting from long-term treatment with oral
glucocorticoids, the lowest 10-year fracture probability
corresponding to that currently reimbursed in Switzerland
was 8.7% in men and 15.0% in women. As shown in
Table 5, several pairs of other risk factors gave an
equivalent or higher fracture probability level. Similarly,
with the treatment threshold set at ≤−2.5 SD as required for
reimbursement of drug therapy of osteoporosis, the
corresponding 10-year fracture probabilities were 11.0%
in men and 14.0% in women. At a T-score of −1.0 SD,
several pairs of associated clinical risk factors resulted in
fracture probabilities higher than that achieved for this
threshold. These were exceeded even more frequently
when more than two risk factors were present in the same
patient.
Fig. 2 Absolute 10-year major fracture probability by age and
femoral neck BMD in Swiss men and women. BMI was set at
25 kg/m2
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Discussion
The present study shows that levels of 10-year fracture
probability equivalent to those currently accepted for reim-
bursement of BMD measurement by DXA in Switzerland
are achieved with several clinical risk factor profiles and
combinations. These include risk factors not (yet) accepted for
reimbursement, such as a parental history of fracture, tobacco
and/or alcohol abuse and rheumatoid arthritis. This suggests
that, with identical 10-year fracture probabilities, adequate
diagnostic workup is not equally accessible to all patients
presenting with identical fracture risk. Consequently, with
current access to osteoporosis diagnosis, too few patients at
increased probability of fracture are adequately identified and
subsequently treated. This is consistent with earlier reports in-
dicating that a significant proportion of osteoporotic fractures
occur in patients with a T-score above −2.5 SD [11, 12].
Low bone mass, as measured by DXA, is an important
single predictor of fracture risk [31–34], and BMD mea-
sured at the femoral neck has been shown to outperform
clinical risk factors alone at all ages for hip fracture
prediction [13]. However, as shown by the present findings,
BMD alone does not capture all determinants of fracture
probability, and the consideration of additional risk factors
Osteoporotic fracturea Hip fracture
50 60 70 80 50 60 70 80
Men
No clinical risk factors 3.4 5.4 7.2 12.0 0.2 0.5 1.6 4.8
Current cigarette smoking 3.6 5.6 7.5 12.0 0.3 0.7 2.2 6.1
Alcohol intake>2 units daily 4.1 6.5 9.0 15.0 0.3 0.8 2.4 7.2
Rheumatoid arthritis 4.6 7.3 10.0 17.0 0.3 0.9 2.8 8.2
Oral glucocorticoids 5.5 8.5 11.0 16.0 0.4 1.0 3.0 7.9
Previous fragility fracture 7.3 11.0 13.0 19.0 0.7 1.5 3.4 7.3
Parental history of hip fracture 6.8 10.0 11.0 22.0 0.2 0.7 3.4 15.0
Women
No clinical risk factors 4.3 8.1 14.0 27.0 0.3 0.8 2.8 10.0
Current cigarette smoking 4.5 8.6 15.0 30.0 0.4 1.2 4.2 14.0
Alcohol intake>2 units daily 5.1 9.7 17.0 33.0 0.4 1.2 4.3 15.0
Rheumatoid arthritis 5.8 11.0 19.0 37.0 0.5 1.4 5.0 17.0
Oral glucocorticoids 7.0 13.0 22.0 40.0 0.6 1.7 5.8 19.0
Previous fragility fracture 9.1 16.0 25.0 42.0 1.1 2.3 5.9 15.0
Parental history of hip fracture 8.4 15.0 22.0 44.0 0.4 1.1 6.0 30.0
Table 2 Ten-year probability
(in per cent) of a major osteopo-
rotic or hip fracture in men and
women according to age and the
presence of a single risk factor
Rows in italics indicate clinical
risk factors included in FRAX®
and currently accepted for DXA
reimbursement in Switzerland.
BMI set at 25 kg/m2
a Hip, clinical spine, humeral or
forearm fracture
Table 1 Ten-year probability (in per cent) of a major osteoporotic or hip fracture in men and women according to the presence of a single risk
factor
Without BMD T-score=−2.5 SD
Men Women Men Women
Osteoporotica Hip Osteoporotica Hip Osteoporotica Hip Osteoporotica Hip
No clinical risk factors 5.6 0.9 9.5 1.5 11.0 4.0 14.0 3.4
Current cigarette smoking 5.9 1.3 10.0 2.2 12.0 6.4 15.0 5.7
Alcohol intake>2 units daily 6.9 1.3 12.0 2.2 14.0 6.1 17.0 5.1
Rheumatoid arthritis 7.7 1.6 13.0 2.6 14.0 5.7 18.0 4.8
Oral glucocorticoids 8.7 1.8 15.0 3.1 17.0 7.0 22.0 6.2
Previous fragility fracture 11.0 2.2 18.0 3.6 18.0 6.6 22.0 5.6
Parental history of hip fracture 11.0 1.2 18.0 1.9 18.0 4.2 24.0 3.6
Rows in italics indicate clinical risk factors included in FRAX® and currently accepted for DXA reimbursement in Switzerland. BMI set at 25 kg/
m2 , age set at 65 years
a Hip, clinical spine, humeral, or forearm fracture
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Table 4 Ten-year probability (in per cent) of a major osteoporotic or hip fracture in men and women with multiple risk factors as a function of
Femoral neck BMD
Without BMD BMD T-score=−2.5 SD BMD T-score=−1.0 SD
Osteoporotic
fracturea
Hip fracture Osteoporotic
fracturea
Hip fracture Osteoporotic
fracturea
Hip fracture
Men
No clinical risk factors 5.6 0.9 11.0 4.0 5.8 0.9
Current cigarette smoking 5.9 1.3 12.0 6.4 5.9 1.5
+Alcohol intake>2 units daily 7.3 1.9 16.0 9.6 7.4 2.3
+Rheumatoid arthritis 10.0 3.4 21.0 13.0 9.7 3.3
+Oral glucocorticoids 16.0 6.5 32.0 21.0 15.0 5.7
+Previous fragility fracture 31.0 15.0 46.0 33.0 24.0 9.3
+Parental history of hip fracture 46.0 20.0 58.0 34.0 37.0 9.8
Women
No clinical risk factors 9.5 1.5 14.0 3.4 7.9 0.7
Current cigarette smoking 10.0 2.2 15.0 5.7 8.0 1.2
+Alcohol intake>2 units daily 13.0 3.3 19.0 8.6 9.7 1.8
+Rheumatoid arthritis 18.0 5.8 25.0 12.0 13.0 2.5
+Oral glucocorticoids 29.0 12.0 39.0 21.0 20.0 4.7
+Previous fragility fracture 51.0 27.0 56.0 33.0 31.0 7.7
+Parental history of hip fracture 71.0 34.0 72.0 34.0 51.0 8.1
BMI set at 25 kg/m2 , age set at 65 years
The sign “+” indicates that the individual risk factors are successively added (incremental risk)
a Hip, clinical spine, humeral or forearm fracture
Table 3 Ten-year probability (in per cent) of a major osteoporotic fracture in men and women according to Femoral neck BMD and presence of a
single risk factor
Osteoporotic fracturea T-score=
–4.0 SD
T-score=
–3.0 SD
T-score=
–2.5 SD
T-score=
–2.0 SD
T-score=
–1.5 SD
T-score=
–1.0 SD
T-score=
0.0 SD
T-score=
+1.0 SD
Without
BMD
Men
No clinical risk factors 24.0 14.0 11.0 8.6 7.0 5.8 4.5 3.8 5.6
Current cigarette smoking 31.0 17.0 12.0 9.4 7.4 5.9 4.4 3.6 5.9
Alcohol intake>2 units daily 32.0 18.0 14.0 11.0 8.7 7.1 5.4 4.5 6.9
Rheumatoid arthritis 32.0 18.0 14.0 11.0 9.1 7.5 5.8 4.9 7.7
Oral glucocorticoids 36.0 22.0 17.0 13.0 11.0 9.0 7.0 6.0 8.7
Previous fragility fracture 37.0 22.0 18.0 14.0 12.0 9.7 7.6 6.5 11.0
Parental history of hip fracture 33.0 22.0 18.0 15.0 13.0 11.0 9.0 7.9 11.0
Women
No clinical risk factors 30.0 17.0 14.0 11.0 9.0 7.9 6.6 5.6 9.5
Current cigarette smoking 37.0 20.0 15.0 12.0 9.3 8.0 6.4 5.4 10.0
Alcohol intake>2 units daily 38.0 22.0 17.0 13.0 11.0 9.5 7.8 6.6 12.0
Rheumatoid arthritis 38.0 22.0 18.0 14.0 12.0 10.0 8.4 7.2 13.0
Oral glucocorticoids 45.0 27.0 22.0 17.0 14.0 13.0 10.0 8.9 15.0
Previous fragility fracture 45.0 27.0 22.0 18.0 15.0 13.0 11.0 9.3 18.0
Parental history of hip fracture 43.0 29.0 24.0 20.0 17.0 16.0 13.0 11.0 18.0
Rows in italics indicate clinical risk factors included in FRAX® and currently accepted for DXA reimbursement in Switzerland. BMI set at
25 kg/m2 , age set at 65 years
a Hip, clinical spine, humeral or forearm fracture
Boxes indicate the current fracture probability threshold for treatment reimbursement in Switzerland
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improves its predictive value. Screening with DXA alone is
generally not considered sensitive enough, and thus, the
identification of patients with osteoporosis generally relies
on case-finding strategies [1]. Therefore, FRAX® repre-
sents a unique opportunity for identifying those subjects
who should benefit from further diagnostic measures, includ-
ing the assessment of risk factors not captured by FRAX®
such as risk factors for falls, gastrointestinal malabsorption
syndromes, increased biochemical markers of bone turnover
and/or vitamin D insufficiency. The need for additional
diagnosis by X-ray examination or a laboratory assessment
of calcium phosphate metabolism can also be indicated
following FRAX® assessment. Depending on the findings
and the T-score value measured at the femoral neck and its
deviation from the mean T-score value in a population of the
same age and sex, the absolute 10-year fracture probability
may assist in determining which patients would benefit from
treatment. Previous analysis of population-based screening
with DXA followed by alendronate treatment, in the presence
of osteoporosis or of fracture and osteopenia, has been shown
to be cost-effective in postmenopausal women after the age of
70 years for the Swiss healthcare system [35]. A FRAX®-
based pre-identification of patients eligible for DXA is likely
to improve cost-effectiveness by increasing the specificity
and sensitivity of case finding.
An interesting finding of the present analysis was that in
65-year old patients with all risk factors included in the
FRAX® algorithm, a T-score of −2.5 SD did not increase
fracture probability in women, though it did in men. This
could be related to the fact that BMD T-score is computed
from the NHANES reference range for women. Thus, in
65-year-old women, a T-score of −2.5 SD corresponds
more or less to the average of the female population of that
age with multiple clinical risk factors. In men, however, this
T-score (derived from the female reference range) is lower
than average for men of this age, and a T-score of -2.5 SD
thus adds a significant component to fracture probability.
Setting a treatment cut-off based on a T-score alone does
select patients at increased probability of fracture. However,
it also categorises patients at equal or higher fracture
probability as non-eligible for treatment if additional clinical
risk factors are not integrated in fracture risk assessment. The
determination of the individual 10-year fracture probability
with FRAX® would at least ensure that patients at equal risk
would have equal chances of getting appropriate treatment.
Interestingly, in the field of osteoporosis, treatment access is
usually restricted in accordance with the inclusion criteria of
the fracture endpoint trials. In the vast majority of these
studies, patients were included on the basis of low bone mass
measured by DXA and/or prevalent vertebral fractures [36–
Table 5 Ten-year probability (in per cent) of a major osteoporotic fracture in men and women according to femoral neck BMD and risk factors
combined by pairs
Without BMD With BMD T-Score = -2.5 SD With BMD T-Score = -1.0 SD
N
o 
cl
in
ic
al
 ri
sk
 fa
ct
or
s
Cu
rre
nt
 c
ig
ar
et
te
 s
m
ok
in
g
Al
co
ho
l i
nt
ak
e 
> 
2 
un
its
 d
ai
ly
R
he
um
at
oi
d 
ar
th
rit
is
O
ra
l g
lu
co
co
rti
co
id
s
Pr
ev
io
us
 fr
ag
ilit
y 
fra
ct
ur
e
Pa
re
nt
al
 h
is
to
ry
 o
f h
ip
 fr
ac
tu
re
N
o 
cl
in
ic
al
 ri
sk
 fa
ct
or
s
Cu
rre
nt
 c
ig
ar
et
te
 s
m
ok
in
g
Al
co
ho
l i
nt
ak
e 
> 
2 
un
its
 d
ai
ly
R
he
um
at
oi
d 
ar
th
rit
is
O
ra
l g
lu
co
co
rti
co
id
s
Pr
ev
io
us
 fr
ag
ilit
y 
fra
ct
ur
e
Pa
re
nt
al
 h
is
to
ry
 o
f h
ip
 fr
ac
tu
re
N
o 
cl
in
ic
al
 ri
sk
 fa
ct
or
s
Cu
rre
nt
 c
ig
ar
et
te
 s
m
ok
in
g
Al
co
ho
l i
nt
ak
e 
> 
2 
un
its
 d
ai
ly
R
he
um
at
oi
d 
ar
th
rit
is
O
ra
l g
lu
co
co
rti
co
id
s
Pr
ev
io
us
 fr
ag
ilit
y 
fra
ct
ur
e
Men
No clinical risk factors 5.6 11.0 5.8
Current cigarette smoking 5.9 12.0 5.9
Alcohol intake > 2 units daily 7.3 6.9 16.0 14.0 7.4 7.1
Rheumatoid arthritis 8.2 9.6 7.7 16.0 18.0 14.0 7.7 9.2 7.5
Oral glucocorticoids 9.1 11.0 12.0 8.7 19.0 21.0 22.0 17.0 9.1 11.0 12.0 9.0
Previous fragility fracture 12.0 13.0 15.0 17.0 11.0 20.0 22.0 23.0 27.0 18.0 11.0 12.0 12.0 15.0 9.7
Parental history of hip
fracture 11.0 13.0 14.0 16.0 20.0 11.0 19.0 22.0 23.0 27.0 29.0 18.0 11.0 13.0 14.0 17.0 18.0 11.0
Women
No clinical risk factors 9.5 14.0 7.9
Current cigarette smoking 10.0 15.0 8.0
Alcohol intake > 2 units daily 13.0 12.0 19.0 17.0 9.7 9.5
Rheumatoid arthritis 14.0 16.0 13.0 20.0 22.0 18.0 10.0 12.0 10.0
Oral glucocorticoids 17.0 19.0 21.0 15.0 24.0 27.0 28.0 22.0 13.0 15.0 16.0 13.0
Previous fragility fracture 20.0 22.0 25.0 29.0 18.0 24.0 27.0 28.0 34.0 22.0 13.0 16.0 17.0 21.0 13.0
Parental history of hip
fracture 19.0 21.0 24.0 28.0 32.0 18.0 25.0 28.0 30.0 36.0 37.0 24.0 15.0 18.0 20.0 24.0 25.0 16.0
Italic fonts indicate clinical risk factors included in FRAX® and currently accepted for DXA reimbursement in Switzerland
Boxes indicate the current fracture probability threshold for treatment reimbursement in Switzerland. Higher probabilities indicated in bold fonts
BMI set at 25 kg/m2 , age set at 65 years
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40]. However, in the subgroup post hoc analyses performed
in all these studies, there was no evidence in favour of
differences in efficacy related to the presence or absence of
these clinical risk factors [36–40]. Moreover, several trials
indicate enhanced effectiveness of pharmacologic interven-
tion in patients with higher fracture probabilities as deter-
mined by the FRAX® tool [41, 42].
The clinical risk factor approach in FRAX® should be
considered to be conservative. Calculated fracture proba-
bilities are limited to major clinical osteoporotic fractures, i.e.
those of the hip, spine, distal forearm and proximal humerus.
In the year 2000 in Switzerland, these fractures represented
63% and 76% of all hospitalised fractures [2] and 63% and
71% of total (hospitalised and non-hospitalised) clinical
fractures in the OsteoCare survey [12] in men and women,
respectively. This study only considered clinical fractures,
although the more prevalent morphometric vertebral frac-
tures and deformities also did increase the risk of future
fracture at any site [43]. In addition these fractures are
associated with substantial increases in back pain and
functional limitation due to back pain [44]. Furthermore,
vertebral fractures, including asymptomatic fractures, may
be responsible of a loss in height. In these patients, BMI
derived from body weight (kilogram) and height (square
meter) will be mathematically higher, leading to a theoretical
underestimation of fracture probability. Therefore, true frac-
ture incidence and derived fracture probabilities are generally
likely to be underestimated. In contrast, the validated risk
factors independent of BMD used in FRAX® modelling are
those that allow consistent linking with BMD T-scores, age,
and BMI in nine international cohorts [13]. This suggests that
still other risk factors may also independently contribute to
fracture risk but are not accommodated in the FRAX®
algorithm. As an example, the history of falls, propensity to
falling, biochemical markers of bone turnover and vitamin D
status are important determinants of fracture probability not
included in FRAX®. Moreover, the magnitude of the effect
on fracture probability of some of the validated risk factors
used in FRAX®, for which the model assumes average
exposure, may depend on dosage, quantity and/or duration of
exposure. In particular, the individual circumstances of the use
of glucocorticoids, tobacco smoking and alcohol consumption
will affect the individual fracture probability. Currently, the
FRAX® tool does not integrate a dose-dependent influence.
Finally, BMDmeasured at other sites than the femoral neck is
a proven risk factor for fractures, which is not included in
FRAX®. FRAX® results also do not integrate BMD increases
achieved with previous or ongoing drug therapies against
osteoporosis. The present study cannot address these issues.
Therefore, one of the key determinants for adequate inter-
pretation of the individual 10-year probability of fracture
delivered by FRAX® will remain clinical judgement.
The findings of the present study are consistent with the
need for a paradigm shift in osteoporosis management. The
current, solely BMD threshold-dependent prevention/
treatment concept needs to evolve to a fracture probability
continuum for which new intervention thresholds, based on
the 10-year probability of any major osteoporotic or hip
fractures, need to be defined. FRAX® based future cost-
effectiveness analyses will certainly contribute to identifying
medically and economically optimised osteoporosis case-
finding strategies.
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